Kuhlmann Julien, Keaei Mussa, Conde Rafael, Evers Silvia M A A, Gonzalez Javier, Govers Mark, Hiligsmann Mickael
Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands.
Asistencia Cientifica de Alta Complejidad, Bogotá, Colombia; Rosario University, Bogotá, Colombia.
Value Health Reg Issues. 2017 Dec;14:103-107. doi: 10.1016/j.vhri.2017.09.002. Epub 2017 Nov 1.
In 2014, 0.3% of the total population in Colombia was living with HIV/AIDS. The data currently available regarding the costs of these patients are very limited.
To estimate the societal costs of patients with HIV/AIDS in Bogotá, Colombia.
This study is a quantitative, cross-sectional cost-of-illness study. Costs were assessed with a prevalence-based, bottom-up approach. The data of 124 patients were collected from their medical records in a Bogotá hospital and a questionnaire was developed to measure other health care costs, as well as patient and family costs. Subgroup analyses were performed according to sex, age, Centers for Disease Control and Prevention classification, and CD4 count (cluster of differentiation 4).
The mean annual cost per patient with HIV/AIDS was estimated at $11,505 ± 18,658 (2014 US dollars). The larger part was attributable to drug costs (a mean annual cost of $8,616, 75% of the total), whereas productivity costs represented a mean annual cost of $1,044 (10%). Total costs per patient were estimated for a CD4 count of 500 or more, 200 to 499, and less than 200 cells/µl at $13,116, $9,077, and $10,741, respectively (all values in 2014 US dollars).
HIV/AIDS represents a high societal burden in Colombia. In comparison with the gross domestic product per capita of $7,904 in 2014, the mean annual cost per patient with HIV/AIDS was 40% higher, estimated at $11,505. The largest part of the HIV/AIDS costs was attributed to drugs, followed by productivity costs. Using extrapolation, the total cost of HIV/AIDS for the Colombian society would be $1.431 billion.
2014年，哥伦比亚总人口中有0.3%的人感染了艾滋病毒/艾滋病。目前关于这些患者治疗费用的可用数据非常有限。
估算哥伦比亚波哥大艾滋病毒/艾滋病患者的社会成本。
本研究是一项定量的横断面疾病成本研究。采用基于患病率的自下而上方法评估成本。从波哥大一家医院的124名患者的病历中收集数据，并设计了一份问卷来衡量其他医疗保健成本以及患者和家庭成本。根据性别、年龄、疾病控制和预防中心分类以及CD4细胞计数（分化抗原簇4）进行亚组分析。
艾滋病毒/艾滋病患者的平均年度成本估计为11,505美元±18,658美元（2014年美元）。其中大部分归因于药物成本（平均年度成本为8,616美元，占总成本的75%），而生产力成本的平均年度成本为1,044美元（10%）。CD4细胞计数为500或更多、200至499以及低于200个细胞/微升的患者的总成本分别估计为13,116美元、9,077美元和10,741美元（所有数值均为2014年美元）。
艾滋病毒/艾滋病在哥伦比亚造成了很高的社会负担。与2014年人均国内生产总值7,904美元相比，艾滋病毒/艾滋病患者的平均年度成本高出40%，估计为11,505美元。艾滋病毒/艾滋病成本的最大部分归因于药物，其次是生产力成本。通过推断，哥伦比亚社会艾滋病毒/艾滋病的总成本将达到14.31亿美元。
